共 148 条
- [1] Raghu G(2018)Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline Am J Respir Crit Care Med 198 e44-e68
- [2] Remy-Jardin M(2013)Health-related quality of life in idiopathic pulmonary fibrosis: where are we now? Curr Opin Pulm Med 19 474-479
- [3] Myers JL(2017)Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities Lancet Respir Med 5 72-84
- [4] Richeldi L(2019)The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry Respir Res 20 59-1769
- [5] Ryerson CJ(2011)Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials Lancet (London, England) 377 1760-926
- [6] Lederer DJ(2010)Development and validity testing of an IPF-specific version of the St George’s respiratory questionnaire Thorax 65 921-810
- [7] Belkin A(2019)Validation of the IPF-specific version of St. George’s respiratory questionnaire Respir Res 20 199-770
- [8] Swigris JJ(2012)The development and validation of the King’s Brief Interstitial Lung Disease (K-BILD) health status questionnaire Thorax 67 804-1455
- [9] King CS(2019)Validation of the King’s Brief Interstitial Lung Disease questionnaire in Idiopathic Pulmonary Fibrosis BMC Pulm Med 19 255-58
- [10] Nathan SD(2018)Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial Lancet Respir Med 6 759-824